Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedApr 10, 2026
DataAggregated Company Financials
Companies7
  • 7D-1.6%
  • 3M-7.7%
  • 1Y-0.09%
  • YTD-3.4%

Over the last 7 days, the Life Sciences industry has dropped 1.3%, driven by Lonza Group declining 1.2%. This takes the industry's 12 month performance to a gain of 3.6%. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 10 Apr 2026CHF 47.2bCHF 10.1bCHF 1.1b32x41.3x4.7x
Sun, 08 Mar 2026CHF 46.7bCHF 10.1bCHF 1.3b28.4x36.2x4.6x
Tue, 03 Feb 2026CHF 50.5bCHF 10.1bCHF 1.3b32.8x39.6x5x
Thu, 01 Jan 2026CHF 49.3bCHF 10.6bCHF 1.1b29.7x44.9x4.6x
Sat, 29 Nov 2025CHF 49.5bCHF 10.6bCHF 1.1b28.4x45x4.6x
Mon, 27 Oct 2025CHF 53.2bCHF 10.6bCHF 1.1b31.4x48.4x5x
Wed, 24 Sep 2025CHF 50.5bCHF 10.6bCHF 1.1b33.9x45.8x4.7x
Fri, 22 Aug 2025CHF 53.6bCHF 10.7bCHF 1.1b36.3x48.4x5x
Sun, 20 Jul 2025CHF 53.1bCHF 10.1bCHF 1.0b33.2x51.1x5.3x
Tue, 17 Jun 2025CHF 52.8bCHF 10.1bCHF 1.0b32.3x50.8x5.2x
Thu, 15 May 2025CHF 53.0bCHF 10.1bCHF 1.0b32.9x51x5.2x
Sat, 12 Apr 2025CHF 48.0bCHF 10.1bCHF 1.0b28.1x46.8x4.8x
Mon, 10 Mar 2025CHF 53.9bCHF 10.1bCHF 1.0b30.1x51.6x5.3x
Wed, 05 Feb 2025CHF 57.5bCHF 10.1bCHF 1.0b35.8x57.2x5.7x
Fri, 03 Jan 2025CHF 52.7bCHF 10.2bCHF 943.4m35.5x55.8x5.2x
Sun, 01 Dec 2024CHF 53.4bCHF 10.2bCHF 943.6m41x56.6x5.2x
Tue, 29 Oct 2024CHF 55.7bCHF 10.2bCHF 943.5m42.6x59x5.5x
Thu, 26 Sep 2024CHF 55.0bCHF 10.2bCHF 943.2m42.1x58.3x5.4x
Sat, 24 Aug 2024CHF 58.1bCHF 10.2bCHF 936.8m45.6x62x5.7x
Mon, 22 Jul 2024CHF 54.0bCHF 10.3bCHF 1.0b46.8x53.9x5.3x
Wed, 19 Jun 2024CHF 51.1bCHF 10.3bCHF 1.0b43.7x51x5x
Fri, 17 May 2024CHF 56.2bCHF 10.3bCHF 1.0b45.9x56.1x5.5x
Sun, 14 Apr 2024CHF 55.8bCHF 10.3bCHF 1.0b43.9x55.7x5.4x
Tue, 12 Mar 2024CHF 51.4bCHF 10.2bCHF 995.5m47.6x51.6x5x
Thu, 08 Feb 2024CHF 47.3bCHF 10.2bCHF 1.0b41.5x46.4x4.6x
Sat, 06 Jan 2024CHF 40.2bCHF 9.8bCHF 1.5b30.7x26.9x4.1x
Mon, 04 Dec 2023CHF 39.6bCHF 9.8bCHF 1.5b29.4x26.5x4.1x
Wed, 01 Nov 2023CHF 37.1bCHF 9.8bCHF 1.5b25.7x24.9x3.8x
Fri, 29 Sep 2023CHF 46.1bCHF 9.8bCHF 1.5b31.6x30.9x4.7x
Sun, 27 Aug 2023CHF 51.9bCHF 9.8bCHF 1.5b36x34.8x5.3x
Tue, 25 Jul 2023CHF 51.8bCHF 9.8bCHF 1.5b35.6x33.4x5.3x
Thu, 22 Jun 2023CHF 55.1bCHF 9.7bCHF 1.6b34.4x33.7x5.7x
Sat, 20 May 2023CHF 60.8bCHF 9.7bCHF 1.6b39x37.2x6.3x
Mon, 17 Apr 2023CHF 61.4bCHF 9.7bCHF 1.7b42.3x36.8x6.3x
Price to Earnings Ratio

36.8x


Total Market Cap: CHF 61.4bTotal Earnings: CHF 1.7bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 41.5x which is lower than its 3-year average PE of 46.0x.
  • The industry is trading close to its 3-year average PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 12% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.40%
Healthcare-0.45%
Life Sciences-1.58%
Clinical Research and Equipment-1.58%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SKAN SKAN GroupCHF 43.101.7%
+CHF 15.7m		-28.8%PE59.5x
XLS Xlife SciencesCHF 21.509.1%
+CHF 10.4m		13.2%PE4x

Latest News

SKAN
CHF 43.10
SKAN Group
7D
1.7%
1Y
-28.8%
LONN
CHF 506.20
Lonza Group
7D
-1.2%
1Y
-3.0%

Lonza Group's (VTX:LONN) Solid Earnings Are Supported By Other Strong Factors

Apr 09
Lonza Group's (VTX:LONN) Solid Earnings Are Supported By Other Strong Factors
TECN
CHF 131.60
Tecan Group
7D
-2.8%
1Y
-6.3%

TECN: Mixed Research Views And 2026 Guidance Shape Forward Expectations

Analysts have trimmed their average price target on Tecan Group to CHF 205, a CHF 17 reduction from recent levels. This reflects updated views on discount rates, revenue growth, profit margins and future P/E assumptions following mixed target moves across the Street.
BANB
CHF 63.50
Bachem Holding
7D
-4.9%
1Y
37.3%

BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential

Narrative Update Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work. Analyst Commentary Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.
SFZN
CHF 76.40
Siegfried Holding
7D
-1.7%
1Y
-7.3%

SFZN: Reset Expectations And Recent Downgrade Will Support Future Upside Potential

Analysts have trimmed their price target for Siegfried Holding by CHF 3.60 to CHF 104.60, reflecting updated assumptions for fair value, discount rate and earnings profile following recent research. This includes a reduced CHF 96 target from RBC Capital and a downgrade in their rating.
PPGN
CHF 29.35
PolyPeptide Group
7D
-1.5%
1Y
103.5%
XLS
CHF 21.50
Xlife Sciences
7D
9.1%
1Y
13.2%